secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001746473-22-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q2 net loss $29.5M; pro-forma cash $379.8M after $215.7M offering
--------------------------------------------------------------------------------

- Net loss of $29.5M in Q2 2022 vs $22.8M in prior-year quarter; R&D expenses $26.3M (up from $19.2M).
- Pro-forma cash, cash equivalents and short-term investments of $379.8M as of June 30, 2022.
- PLN-74809 INTEGRIS-IPF Phase 2a met primary endpoint; dose-dependent effects on FVC and QLF observed.
- FDA Fast Track designation for PLN-74809 in PSC; topline data from INTEGRIS-PSC expected H1 2023.
- Received $4.0M milestone from Novartis collaboration; loan facility with Oxford Finance provides up to $100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647322000025/0001746473-22-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647322000025/plrx-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001746473-22-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer